John Nicoll

5.8k citations

30 papers · 3.2k indexed · 2 hit papers · h-index 18

Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments 21
- Acute Myeloid Leukemia Research 4
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 17
- Myeloproliferative Neoplasms: Diagnosis and Treatment 3
Rheumatology top 1%
- Eosinophilic Disorders and Syndromes 10
Cancer Research top 5%
Pathology and Forensic Medicine top 5%
- Whipple's Disease and Interleukins 4
Organic Chemistry
- Click Chemistry and Applications 2
Immunology
- Mast cells and histamine 2

Co-authors: Charles L. Sawyers Ronald Paquette Neil P. Shah Eric Bleickardt Claude Nicaise Moshe Talpaz Hagop M. Kantarjian Arthur P. DeCillis
Cited by: Hematology Genetics Rheumatology
Journals: Blood (12 papers)The Journal of Immunology (4 papers)Journal of Clinical Oncology (3 papers)
Partner nations: United States Australia United Kingdom

In The Last Decade

John Nicoll

30 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by John Nicoll

Since Specialization

Citations

This map shows the geographic impact of John Nicoll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Nicoll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Nicoll more than expected).

Fields of papers citing papers by John Nicoll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Nicoll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Nicoll. The network helps show where John Nicoll may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John Nicoll, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Nicoll Line = papers co-authored together John Nicoll links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors Cancer Genetics ·Ronald Paquette,John Nicoll,Meenal Chalukya,David Elashoff,Neil P. Shah,Charles L. Sawyers,Elizabeth Spiteri,Gouri J. Nanjangud,P. Nagesh Rao	2011	28
2	CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia Blood ·Hideki Makishima,Anna Jankowska,Michael A. McDevitt,Christine L. O’Keefe,Simon Dujardin,Heather Cazzolli,Bartlomiej Przychodzen,Courtney Prince,John Nicoll,Kayla Antosz,Mohammed Shaik,Hadrian Szpurka,Eric D. Hsi,Anjali S. Advani,Ronald Paquette,Jaroslaw P. Maciejewski	2011	106
3	Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib Leukemia Research ·Ronald Paquette,John Nicoll,Meenal Chalukya,A López Gudino,Monika Jasek,Charles L. Sawyers,Neil P. Shah,Jaroslaw P. Maciejewski	2009	2
4	Pha-739358: a pan-aurora kinase inhibitor Ronald Paquette,Neil P. Shah,Charles L. Sawyers,Giovanni Martinelli,John Nicoll,Meenal Chalukya	2009	3
5	Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorderbreakdown → The Journal of Experimental Medicine ·Ryan M. O’Connell,Dinesh S. Rao,Aadel A. Chaudhuri,Mark Boldin,Konstantin D. Taganov,John Nicoll,Ronald Paquette,David Baltimore	2008	557
6	Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis Cancer Cell ·Neil P. Shah,Corynn Kasap,Christopher Weier,Minna Balbas,John Nicoll,Eric Bleickardt,Claude Nicaise,Charles L. Sawyers	2008	181
7	Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency Journal of Clinical Investigation ·Neil P. Shah,Brian J. Skaggs,Susan Branford,Timothy P. Hughes,John Nicoll,Ronald Paquette,Charles L. Sawyers	2007	288
8	Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemiasbreakdown → New England Journal of Medicine ·Moshe Talpaz,Neil P. Shah,Hagop M. Kantarjian,Nicholas J. Donato,John Nicoll,Ron Paquette,Jörge E. Cortes,Susan O’Brien,Claude Nicaise,Eric Bleickardt,Alice Monteze Santos de Barros,Vishwanath R. Iyer,Tai‐Tsang Chen,Fei Huang,Arthur P. DeCillis,Charles L. Sawyers	2006	1288
9	The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy. Blood ·Neil P. Shah,Brian J. Skaggs,Susan Branford,Timothy P. Hughes,John Nicoll,Ronald Paquette,Charles L. Sawyers	2006	6
10	Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors. Blood ·Neil P. Shah,Brian J. Skaggs,Susan Branford,Timothy P. Hughes,John Nicoll,Ronald Paquette,Charles L. Sawyers	2006	8
11	Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development. Blood ·Neil P. Shah,John Nicoll,Eric Bleickardt,Claude Nicaise,Ronald Paquette,Charles L. Sawyers	2006	8
12	A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002 Journal of Clinical Oncology ·Moshe Talpaz,Hagop M. Kantarjian,Ron Paquette,Neil P. Shah,Jörge E. Cortes,John Nicoll,S A Bai,Fei Huang,Arthur P. DeCillis,Charles L. Sawyers	2005	27
13	Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL) Journal of Clinical Oncology ·Neil P. Shah,Charles L. Sawyers,Hagop M. Kantarjian,C. Wisset,John Nicoll,Jörge E. Cortes,Ron Paquette,Fei Huang,Edwin Clark,Moshe Talpaz	2005	9
14	Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy. Blood ·Neil P. Shah,John Nicoll,Susan Branford,Timothy P. Hughes,Ronald Paquette,Moshe Talpaz,Claude Nicaise,Fei Huang,Charles L. Sawyers	2005	12
15	Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients. Blood ·Susan Branford,Timothy P. Hughes,John Nicoll,Ron Paquette,Eric Bleickardt,Charles L. Sawyers,Neil P. Shah	2005	5
16	Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. Blood ·Charles L. Sawyers,Neil P. Shah,Hagop M. Kantarjian,Nicholas J. Donato,John Nicoll,Stephen A. Bai,Fei Huang,Edwin Clark,Arthur P. DeCillis,Moshe Talpaz	2004	42
17	Processing and Release of IL-16 from CD4+ But Not CD8+ T Cells Is Activation Dependent The Journal of Immunology ·Jean Carlo Kohmann,Yujun Zhang,Nereida A. Parada,Hardy Kornfeld,John Nicoll,William W. Cruikshank	1999	73
18	Identification of Domains in IL-16 Critical for Biological Activity The Journal of Immunology ·John Nicoll,William W. Cruikshank,William Brazer,献群郭,Hardy Kornfeld	1999	28
19	Conservation of Structure and Function Between Human and Murine IL-16 The Journal of Immunology ·Joseph Keane,John Nicoll,Sue Kim,Jean Carlo Kohmann,William W. Cruikshank,William Brazer,雷文辉,Yujun Zhang,Hardy Kornfeld	1998	55
20	CD4 ligand IL-16 inhibits the mixed lymphocyte reaction The Journal of Immunology ·Arthur C. Theodore,John Nicoll,Gregg Fine,Hardy Kornfeld,William W. Cruikshank	1996	88

About John Nicoll

John Nicoll is a scholar working on Hematology, Genetics, Rheumatology, Pathology and Forensic Medicine and Immunology, having authored 30 papers that have together received 3.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (21 papers), Chronic Lymphocytic Leukemia Research (17 papers), Eosinophilic Disorders and Syndromes (10 papers), Acute Myeloid Leukemia Research (4 papers), Whipple's Disease and Interleukins (4 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Click Chemistry and Applications (2 papers) and Mast cells and histamine (2 papers). The work is most often cited by research in Hematology (1.9k citations), Genetics (1.4k citations), Rheumatology (919 citations), Cancer Research (535 citations) and Pathology and Forensic Medicine (338 citations). John Nicoll has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Charles L. Sawyers, Ronald Paquette, Neil P. Shah, Eric Bleickardt, Claude Nicaise, Moshe Talpaz, Hagop M. Kantarjian, Arthur P. DeCillis, Fei Huang and Nicholas J. Donato. Their work appears in journals such as Blood, The Journal of Immunology, Journal of Clinical Oncology, Cancer Cell and The Journal of Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact